Leonhardt Ventures Announces E-Stent™ Platform for Wireless Bioelectric Protein Control in Vascular Implants
TL;DR
Leonhardt Ventures' E-Stent technology offers exclusive licensing opportunities across 29 medical applications, creating first-mover advantages in regenerative medicine markets.
The E-Stent system uses wireless wearable harnesses to deliver bioelectric signals through micro-coils embedded in stents, controlling specific protein expressions for targeted regeneration.
This wireless bioelectric stent platform could significantly improve treatment outcomes for conditions ranging from Alzheimer's to heart disease, potentially enhancing millions of lives worldwide.
Leonhardt Ventures' wireless E-Stent can stimulate proteins like klotho and sirtuins to regenerate organs from brain to pancreas using bioelectric signals.
Found this article helpful?
Share it with your network and spread the knowledge!
Leonhardt Ventures LLC has announced the development of E-Stent™, a wireless bioelectric protein-expression stent platform designed to activate or inhibit specific regenerative proteins directly from vessel walls and surrounding tissues. The technology combines a next-generation implant with a wireless wearable harness that delivers controlled protein expressions to micro-coils embedded along the stent, with sizes ranging from micro-implants smaller than a pea to 28 mm aortic stents. According to Brian Lasater, CTO of Leonhardt Ventures LLC and Lionheart Health, Inc., working prototypes are currently in testing that can control regenerative and healing protein expressions on demand through wireless energy. The platform represents an evolution of the company's previously announced KlothoImplant Bioelectric MicroImplant technology, expanding similar capabilities into advanced vascular implant formats.
The company has granted exclusive licenses for the E-Stent™ platform across 29 specialized medical applications. These include KidneyCell™ for kidney regeneration, CerebraCell™ for brain health and stroke recovery, AddictiStim™ for addiction treatment, and MemoryStim™ for memory improvement and Alzheimer's treatment. Other licensed applications include DepressiStim™ for severe depression, CancerCell™ for cancer treatment, and Lionheart Health for healthspan longevity. Additional licensed applications include Vascustim™ for peripheral artery disease, AortaCell™ for aortic aneurysm treatment, SpineStim™ for spinal cord injury recovery, and BioPace™ for biological pacemaker regeneration. The platform also addresses orthopedic applications through OrthoStim™ and dental applications via DentaCell™.
The technology platform can stimulate or inhibit a broad range of proteins including klotho, sestrins, sirtuins, apelin, LIM, CXCL5, tropoelastin, COL17A1, SDF1, PDGF, NANOG, RANK-L, BMP9, OPG, VEGF, S100a, HIF1a, BDNF, Sonic Hedgehog, TGFb, and FABp4 downregulation. These stimulations can direct stem cell homing, proliferation, and differentiation on demand, potentially improving circulation, restoring muscle strength, modulating inflammation and blood pressure, improving nerve connections, and restoring elasticity. Lionheart Health, majority owned by Leonhardt Ventures LLC, was recently recognized by Medtech Outlook Magazine as Micro Implant Stimulator Development of the Year 2025. The company was also recognized as Abbvie Allergan ULP Innovation of the Year in Medical Aesthetics and as a top 40 semi-finalist in the $101 Million Xprize Healthspan competition. All products remain in clinical studies and are not yet proven to be safe or effective.
Curated from Newsworthy.ai
